Journal
THORAX
Volume 77, Issue 3, Pages 304-311Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2021-217260
Keywords
opportunist lung infections; lung cancer; lung cancer chemotherapy; tuberculosis; aspergillus lung disease; viral infection; bacterial infection
Categories
Funding
- MRC [MR/P023754/1] Funding Source: UKRI
Ask authors/readers for more resources
Immune checkpoint inhibitors (ICIs) have greatly impacted cancer treatment, but immune-related adverse events (irAEs) and infections caused by immunosuppression are common issues. However, some infections can be triggered by ICIs without immunosuppressive treatment, characterized by dysregulated immune responses. A new framework is needed to consider such infections in the context of cancer immunotherapy.
Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment. However, immune-related adverse events (irAEs) are a common side effect which can mimic infection. Additionally, treatment of irAEs with corticosteroids and other immunosuppressant agents can lead to opportunistic infection, which we have classed as immunotherapy infections due to immunosuppression. However, emerging reports demonstrate that some infections can be precipitated by ICIs in the absence of immunosuppressive treatment, in contrast to the majority of reported cases. These infections are characterised by a dysregulated inflammatory immune response, and so we propose they are described as immunotherapy infections due to dysregulated immunity. This review summarises the rapidly emerging evidence of these phenomena and proposes a new framework for considering infection in the context of cancer immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available